REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $619.64 million. The enterprise value is $366.16 million.
| Market Cap | 619.64M |
| Enterprise Value | 366.16M |
Important Dates
The next estimated earnings date is Wednesday, July 31, 2024, after market close.
| Earnings Date | Jul 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 49.26 million shares outstanding. The number of shares has increased by 5.25% in one year.
| Shares Outstanding | 49.26M |
| Shares Change (YoY) | +5.25% |
| Shares Change (QoQ) | +3.93% |
| Owned by Insiders (%) | 7.32% |
| Owned by Institutions (%) | 91.28% |
| Float | 40.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.14 |
| Forward PS | 6.06 |
| PB Ratio | 1.59 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.59 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.81 |
Financial Efficiency
Return on equity (ROE) is -70.70% and return on invested capital (ROIC) is -55.62%.
| Return on Equity (ROE) | -70.70% |
| Return on Assets (ROA) | -41.30% |
| Return on Capital (ROIC) | -55.62% |
| Revenue Per Employee | $252,110 |
| Profits Per Employee | -$756,244 |
| Employee Count | 344 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -152,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.37% in the last 52 weeks. The beta is 1.26, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -31.37% |
| 50-Day Moving Average | 13.46 |
| 200-Day Moving Average | 16.63 |
| Relative Strength Index (RSI) | 50.19 |
| Average Volume (20 Days) | 686,617 |
Short Selling Information
The latest short interest is 4.32 million, so 8.77% of the outstanding shares have been sold short.
| Short Interest | 4.32M |
| Short Previous Month | 4.56M |
| Short % of Shares Out | 8.77% |
| Short % of Float | 10.62% |
| Short Ratio (days to cover) | 6.22 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $86.73 million and -$260.15 million in losses. Loss per share was -$5.87.
| Revenue | 86.73M |
| Gross Profit | 49.34M |
| Operating Income | -265.83M |
| Pretax Income | -260.30M |
| Net Income | -260.15M |
| EBITDA | -236.90M |
| EBIT | -254.22M |
| Loss Per Share | -$5.87 |
Balance Sheet
The company has $340.73 million in cash and $87.25 million in debt, giving a net cash position of $253.48 million or $5.15 per share.
| Cash & Cash Equivalents | 340.73M |
| Total Debt | 87.25M |
| Net Cash | 253.48M |
| Net Cash Per Share | $5.15 |
| Equity (Book Value) | 390.67M |
| Book Value Per Share | 7.93 |
| Working Capital | 285.24M |
Cash Flow
In the last 12 months, operating cash flow was -$192.94 million and capital expenditures -$5.70 million, giving a free cash flow of -$198.64 million.
| Operating Cash Flow | -192.94M |
| Capital Expenditures | -5.70M |
| Free Cash Flow | -198.64M |
| FCF Per Share | -$4.34 |
Margins
Gross margin is 56.89%, with operating and profit margins of -306.52% and -299.97%.
| Gross Margin | 56.89% |
| Operating Margin | -306.52% |
| Pretax Margin | -300.14% |
| Profit Margin | -299.97% |
| EBITDA Margin | -273.16% |
| EBIT Margin | -293.13% |
| FCF Margin | -229.05% |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.25% |
| Shareholder Yield | -5.25% |
| Earnings Yield | -41.98% |
| FCF Yield | -32.06% |
Analyst Forecast
The average price target for REGENXBIO is $40.50, which is 221.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.50 |
| Price Target Difference | 221.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 45.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -0.8 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.8 |
| Piotroski F-Score | 4 |